You are here: Industry Insights > linperlisib

News List

Pharmaceutical News of August | PharmaSources.com: Approval PharmaSources/Caicai
September 23, 2020
Information on two proposed breakthrough therapies was publicized on the CDE website, separately YY-20394 tablets (linperlisib) of YL-Pharma and plinabulin concentrated solution for injection of BeyondSpring.
Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2 prnasia
June 11, 2021
Yingli Pharma announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021.
Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annu prnasia
June 04, 2021
Shanghai Yingli Pharmaceuticals Ltd announced today that there will be three presentations on clinical trials sponsored by the company at the annual meeting of the American Society for Clinical Oncology (ASCO) June 4-7, 2021.
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib prnasia
April 01, 2021
Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3Kδ inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL).